- Home
- MIRM vs MTN Comparison
MIRM vs MTN Comparison
Compare MIRM & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | MTN |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.4B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MIRM | MTN |
|---|---|---|
| Price | $101.19 | $135.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $119.85 | ★ $162.58 |
| AVG Volume (30 Days) | ★ 1.0M | 582.3K |
| Earning Date | 05-06-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 7.27% |
| EPS Growth | ★ 74.59 | 24.05 |
| EPS | N/A | ★ 0.65 |
| Revenue | $19,138,000.00 | ★ $2,964,347,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | $6.42 |
| P/E Ratio | ★ N/A | $206.36 |
| Revenue Growth | N/A | ★ 2.74 |
| 52 Week Low | $43.50 | $118.51 |
| 52 Week High | $114.99 | $172.00 |
Technical Indicators
Market Signals| Indicator | MIRM | MTN |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 65.01 |
| Support Level | $95.68 | $132.02 |
| Resistance Level | $107.51 | $135.42 |
| Average True Range (ATR) | 5.22 | 3.78 |
| MACD | -0.65 | 1.50 |
| Stochastic Oscillator | 33.42 | 89.36 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.